Proteomics in drug development

Incomplete knowledge of the real-time biology underlying disease and drug action can drive up costs and time in drug development. Protein biomarkers, along with other omics markers, can be used to predict response, stratify patient populations, and provide insights into the biology of disease.

Olink offers a high-throughput solution for protein biomarker discovery with thousands of thoroughly validated assays that provide exceptional specificity at high-multiplex levels and has been widely used in clinical biomarker research. It can be applied across all stages of drug development, from early discovery through preclinical and clinical development to post-approval activities such as post-market surveillance and label expansion.

Key applications to address the major challenges of drug development

Escalating costs and increasing demands from regulatory authorities for a more precision medicine-based approach to drug development are substantial challenges for the pharmaceutical industry. Faster drug discovery with increased probability of successful implementation of new therapies can be greatly facilitated by multiomics approaches that can enable deep knowledge of the biology underlying human disease and provide actionable insights to accelerate key decision making. Proteomics is now taking center stage in these approaches, and Olink’s proximity extension assay (PEA) technology is increasingly used in key applications that can accelerate successful drug development.